BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12239305)

  • 1. Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.
    Bryant H; Farrell PJ
    J Virol; 2002 Oct; 76(20):10290-8. PubMed ID: 12239305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
    Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
    J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter sequences required for reactivation of Epstein-Barr virus from latency.
    Binné UK; Amon W; Farrell PJ
    J Virol; 2002 Oct; 76(20):10282-9. PubMed ID: 12239304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.
    McDonald C; Karstegl CE; Kellam P; Farrell PJ
    J Gen Virol; 2010 Mar; 91(Pt 3):622-9. PubMed ID: 19923262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling.
    Gruffat H; Manet E; Sergeant A
    EMBO Rep; 2002 Feb; 3(2):141-6. PubMed ID: 11818339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter.
    Lavens S; Faust EA; Lu F; Jacob M; Leta M; Lieberman PM; Puré E
    J Virol; 2004 Aug; 78(16):8543-51. PubMed ID: 15280463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member.
    Liu S; Liu P; Borras A; Chatila T; Speck SH
    EMBO J; 1997 Jan; 16(1):143-53. PubMed ID: 9009275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter.
    Sun CC; Thorley-Lawson DA
    J Virol; 2007 Dec; 81(24):13566-77. PubMed ID: 17898050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.
    Hergenhahn M; Soto U; Weninger A; Polack A; Hsu CH; Cheng AL; Rösl F
    Mol Carcinog; 2002 Mar; 33(3):137-45. PubMed ID: 11870879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.
    Fahmi H; Cochet C; Hmama Z; Opolon P; Joab I
    J Virol; 2000 Jul; 74(13):5810-8. PubMed ID: 10846060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.
    Ye J; Gradoville L; Miller G
    J Virol; 2010 Dec; 84(23):12405-18. PubMed ID: 20861250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone acetylation and reactivation of Epstein-Barr virus from latency.
    Jenkins PJ; Binné UK; Farrell PJ
    J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
    Gradoville L; Kwa D; El-Guindy A; Miller G
    J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.
    Murata T; Narita Y; Sugimoto A; Kawashima D; Kanda T; Tsurumi T
    J Virol; 2013 Sep; 87(18):10148-62. PubMed ID: 23843637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching of EBV cycles between latent and lytic states.
    Murata T; Tsurumi T
    Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
    J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation.
    Iwakiri D; Takada K
    J Immunol; 2004 Feb; 172(3):1561-6. PubMed ID: 14734735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein-Barr virus BZLF1 promoter.
    Ruf IK; Rawlins DR
    J Virol; 1995 Dec; 69(12):7648-57. PubMed ID: 7494273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The periodontal pathogen Porphyromonas gingivalis induces the Epstein-Barr virus lytic switch transactivator ZEBRA by histone modification.
    Imai K; Inoue H; Tamura M; Cueno ME; Inoue H; Takeichi O; Kusama K; Saito I; Ochiai K
    Biochimie; 2012 Mar; 94(3):839-46. PubMed ID: 22178321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negatively cis-acting elements in the distal part of the promoter of Epstein-Barr virus trans-activator gene BZLF1.
    Schwarzmann F; Prang N; Reichelt B; Rinkes B; Haist S; Marschall M; Wolf H
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():1999-2006. PubMed ID: 8046403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.